A value-based formulary was implemented that used cost-effectiveness analysis to inform medication co-payments. Diabetes cohort expenditures decreased by $9 per member per month.
Zachary A. Marcum, PharmD, PhD
Advertisement
Articles by Zachary A. Marcum, PharmD, PhD
Advertisement
Latest Updated Articles
- Impact of a Value-Based Formulary in Three Chronic Disease Cohorts
Published: March 27th 2017 | Updated:
Advertisement
Advertisement
